Phesi announces AI-driven Trial Accelerator™ hits critical milestone with data from 100 million patients

Date: 02. 12. 2024

Clinical data analytics expert also publishes second version of Digital Patient Profile Catalog, covering six more indications to help make digital twin creation a reality for more diseases

Boston, USA, February 6, 2024: Phesi, a global provider of patient-centric data analytics, has announced it has reached a critical milestone, with its AI-driven Trial Accelerator™ Platform now containing global data from more than 100 million patients. This unparalleled volume of data will allow sponsors to access data on patients with more than 4,000 indications, plan more successful trials, and simulate clinical development activity with a high degree of accuracy.

With such a huge repository of data in Trial Accelerator, Phesi has now also published the second edition of its Digital Patient Profile (DPP) catalogue. Each DPP delivers a statistical view of patient attributes to improve protocol design and accelerate the adoption of digital trial arms. The new DPPs are: Relapsed/ Refractory Follicular Lymphoma, CDKL5, Chronic Migraine, Episodic Migraine, Stroke – Acute Ischemic, and Acute Coronary Syndrome.

“Collating data from 100 million patients is a huge milestone for Phesi. For almost two decades we have been gathering and structuring a wealth of data for sponsors and clinical trial planners,” commented Dr Gen Li, President, Phesi. “Context is key: Phesi is able to identify where and when specific data was generated, by whom (study investigators), and how (study design) to provide contextualized data that delivers precision, insights, and certainty to clinical development teams. We are committed to continuing to innovate and support our clients to make breakthroughs, and deliver smarter cures to patients, faster.”

The second edition of the Digital Patient Profile Catalog contains granular patient data across 34 indications both at cohort level and patient level. The profiles will be used by sponsors to develop Digital Twins and Digital Trial Arms as part of clinical development strategies. DPPs also support wider adoption of single arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts. As well as 12 oncology profiles, the catalog will cover 22 other prevalent diseases. The addition of stroke is particularly crucial, with Phesi’s recent analysis of all clinical trials in 2023 finding that stroke is now the third most-studied disease area worldwide.

“We are continually refining the methodology by which we create patient profiles,” explained Jonathan Peachey, COO and Board Director, Phesi. “In this way, we empower sponsors to make data-led decisions in the trial planning process, as well as enabling them to use digital twins and the next generation of digital control arms. We’ve seen the popularity of digital twins increase, but tools like the Digital Patient Profile are what make these twins a reality.”

The traditional data management function of collecting and interpreting patient data from clinical trials is transforming. Digitalized patient data can be used to enhance or even replace those collected from clinical trials. Phesi’s Trial Accelerator delivers these advances directly to its users. These latest updates to the platform represent an accumulation of almost 20 years’ worth of effort collating data from product and disease registries, data from electronic health records, medical claims data, and data gathered from almost 100,000 dynamically updated sources. A global patent was granted in Dec 2023 from the Japanese Patent Office for Phesi’s method and system of analyzing and optimizing clinical trial protocols; including protocol design optimization and minimizing avoidable protocol amendments. 

Phesi is attending the annual SCOPE Summit from February 11-14, at booth 1021. Please visit https://info.phesi.com/scope_2024 to book a conversation with the Phesi team. 

The Phesi Patient Access Score, Diversity, Equity, and Inclusion (DE&I) Data Service (with Krystelis) and the Digital Patient Profile are powered by the Phesi Trial Accelerator platform.

The latest DPP Catalog is available here: https://info.phesi.com/dpp-jan24.

Related news
01. 16. 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year Read more
10. 15. 2023
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster Read more
09. 07. 2023
Phesi and Krystelis collaborate to launch new Diversity, Equity, and Inclusion Data Service for clinical development Read more
07. 14. 2023
Depression now one of the top five most studied disease areas in clinical development, finds new Phesi global analysis Read more
01. 16. 2023
New Phesi global analysis sees breast cancer retain position as most studied disease area in 2022 Read more
11. 30. 2022
Number of collagen clinical trials more than doubled since 2010, Phesi analysis shows Read more